ArticleBreast cancer research and treatment2025
Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.Breast cancer research and treatment · 2026Trial
- The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDual HER2 blockade with trastuzumab and pertuzumab combined with neoadjuvant chemotherapy improves outcomes in HER2-positive breast cancer. The optimal taxane backbone (paclitaxel vs. docetaxel) remains unclear.
methodsThis retrospective study included 220 HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by dual HER2 blockade with trastuzumab, pertuzumab, and either paclitaxel (80 mg/m
resultsAt the time of diagnosis, 6% of the patients included in the study were at stage I, 70.4% were at stage II, and 23.6% were at stage III. The overall pCR rate was 55%, with no significant difference between the paclitaxel (57.9%) and docetaxel (52.2%) groups (p = 0.418). Higher pCR rates were associated with grade 3 tumors, ER/PR negativity, and Ki- 67 ≥ 20%. Patients achieving pCR had significantly lower relapse rates (2.5% vs. 16.2%, p < 0.001). These factors were significantly associated with pCR in univariate analysis but did not remain independent predictors in multivariate analysis. DFS and OS were higher in the paclitaxel group compared to the docetaxel group (DFS: 96.3% vs. 83.2%, p = 0.025; OS: 100% vs. 95.5%, p = 0.042). Grade 3-4 anemia was more frequent with docetaxel (23% vs. 9%, p = 0.007).
conclusionBoth paclitaxel and docetaxel are effective in neoadjuvant dual HER2 blockade regimens. Paclitaxel demonstrated better DFS, OS, and a favorable safety profile, supporting its use as a preferred option.
Indexed as
Identifiers
40214840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.